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ScienceDirectThe need for scalable strategies to probe the biological
consequences of candidate cancer genes has never been more
pressing. The zebrafish, with its capacity for high-throughput
transgenesis, in vivo imaging and chemical/genetic screening,
has ideal features for undertaking this task. Unique biological
insights from zebrafish have already led to the identification of
novel oncogenic drivers and small molecules being used to
treat the human cancer. This review summarizes the recent
main findings and describes pertinent areas where the
zebrafish can greatly contribute to our understanding of cancer
biology and treatment.
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Introduction
The wealth of genetic and transcriptomic data in cancer
biology, accumulated through international cancer efforts
such as The Cancer Genome Atlas (TCGA) and Inter-
national Cancer Genome Consortium (ICGC), present
unprecedented opportunities for identifying therapeuti-
cally meaningful targets. A major challenge in genomic
approaches has been the lack of appropriate model sys-
tems in which to test these on a large scale. Owing to its
small size, heavy brood, and rapid maturation time, the
zebrafish has emerged as an important new cancer model
that complements what can traditionally be achieved in
mice and cell culture systems. Advances in transgenic and
mutagenesis strategies have already led to a wide variety
of zebrafish cancer models with distinct capabilities for
high-throughput screening and in vivo imaging [1,2,3,
4–16]. Despite significant progress in the past 10 years,§ This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted
use, distribution and reproduction in any medium, provided the original
author and source are credited.
Current Opinion in Genetics & Development 2014, 24:38–45 however, the unique role of zebrafish in cancer research has
still yet to be defined. Here, we review recent major
achievements in the zebrafish cancer field in light of
the available models and advances in genomic techniques.
We conclude by discussing future areas of research where
zebrafish efforts will be the most effective.
Blood tumors
Numerous leukemic lines have been generated since the
first zebrafish model of leukemia was reported in 2003, in
a landmark paper showing that expression of mouse c-Myc
in transgenic zebrafish unleashed rapid leukemia devel-
opment [1]. Consisting of a variety of T or B-cell lym-
phoblastic (ALL) and myeloid (AML) malignancies,
zebrafish leukemia is typically modeled through the
expression of a frequently mutated proto-oncogene (such
as c-Myc [1], TEL-AML [4] and NOTCH1 [6]) under the
rag2 promoter in developing lymphocytes. A major
advantage of this system is the tagging of a fluorescent
marker to the gene of interest, enabling powerful real-
time tracking of lymphocyte migration and proliferation.
An illustrative example of this tool is an elegant work by
Feng et al., in studying a Bcl-2;Myc zebrafish model of
lymphoblastic lymphoma (T-LBL) [17]. In this study, Feng
et al. monitored the local metastatic behavior of Discosoma
red (ds-RED) tagged zebrafish lymphocytes in transparent
casper fish, which had vasculature defined by enhanced
green fluorescence protein (EGFP). Through live imaging
of these cells, the authors were able to determine that
lymphoblastautophagywas responsible forpreventingtheir
intravasion into the marrow, a hallmark transition of T-LBL
to acute T-ALL. Cross-testing in zebrafish and human T-
LBL cell lines revealed that this autophagy was caused by
high levels of S1P1, which when suppressed resulted in
widespread dissemination of the disease (Table 1).
Inanother study, live imaging ofzebrafishembryos enabled
Ridges et al. to identify a selective inhibitor of lymphocyte
proliferation that is remarkably effective against human T-
ALL xenografts [18]. Ridges et al. screened over 26 000
chemicals for activity that could diminish fluorescent-
tagged lymphocyte development in zebrafish larvae. One
compound, lenaldekar, induced long-term remission in a
zebrafish T-ALL model with encouraging responses in
efficacy and toxicity when targeted against human xeno-
grafts in mice. While the drug’s mechanism remains to be
determined, this study provides a key example of the
application of zebrafish for pre-clinical drug discovery.
In contrast to T-ALL, efforts to study acute myeloid
leukemia (AML), the most lethal and commonlywww.sciencedirect.com
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Table 1
Tools for modeling cancer in zebrafish.
Purpose Tool Examples
Mutagenesis for forward genetic screens N-ethyl-N-nitrosourea (ENU) [56] [3,5,57]
Retroviral-based insertional mutagenesis [58] [59]
Transgenesis Tol2 transposon [60,61] [16]
Transgenesis for inducible gene expression GAL4/UAS [62] [63]
Heat-shock Cre/loxP [64,65] [11,20,66,67]
Tet-on [68] [69]
LexPR system [70] [14]
Site-specific mutagenesis Talens [71] [72]
Zinc finger nucleases [73,74] [75]
CRISPr [50] [52]
Selective expression of mutant alleles in somatic tissue Plasmid injection (miniCoopR shuttle vector system) [28] [28]diagnosed leukemia, have not been as successful. To our
knowledge, there is one zebrafish AML model and it is
based on expression of the MOZ/TIF2 (MYST3/NCOA2)
fusion gene under spi1 control in the kidney, where
hematopoiesis occurs in zebrafish [19]. Attempts to model
AML from proto-oncogenes KRASG12D [20], NUP98-
HOXA9 [21] and AML1-ETO [22] have instead led to
new models of myeloproliferative neoplasms (MPN) that
for unknown reasons do not advance to AML. While the
early MPN phenotypes provide valuable read-outs for
chemical-genetic screening [23], their inability to pro-
gress to AML may indicate biological differences in this
system that warrant further investigation.
In spite of these and other exciting discoveries, there
remain areas of active challenge in modeling leukemia in
zebrafish. These include to what extent the models truly
recapitulate basic aspects of the human disease, to what
extent they can be used as models for interrogating
genomic changes, and how they can be most effectively
used to identify new drug targets across a wider range of
disease types. In the coming years, large scale testing of
candidate drivers (culled from the TCGA type efforts) in
zebrafish leukemic lines will be necessary for these
models to further demonstrate their worth.
Solid tumors
Improved transgenic strategies have enhanced the com-
plexity and diversity of solid tumor models in zebrafish,
many of which were established through N-ethyl-N-nitro-
sourea (ENU) mutagenesis screens of mutations in
specific genes of interest, such as the important tumor
suppressor genes tp53, apc and pten [3,5,24]. Here we
focus on two rapidly growing areas of solid tumor model
research: melanoma and embryonal rhabdomyosarcoma.
Melanoma
The first experimental confirmation that oncogenic
BRAFV600E (BRAF), mutated in 40–50% of human mel-
anomas [25–27], can promote nevi (moles) and melanomawww.sciencedirect.com formation was demonstrated in zebrafish [7]. Since then,
similar findings have been shown with NRASQ61K [8]
although this model remains less exploited thus far.
The simplicity of visualizing melanoma development
in these models has led to their widespread adoption
and several important, proof-of-principle experiments.
Using the BRAF model, Ceol et al. [28] tested the
oncogenicity of 30 candidate melanoma cancer genes
found in a region recurrently amplified in human meta-
static melanoma [29]. Genes were overexpressed in mel-
anocytes through the injection of a miniCoopR shuttle
vector system into BRAF and p53 mutant embryos. By
monitoring for accelerated tumor onset, Ceol et al. were
able to identify that SETDB1, a histone transferase, is an
oncogene that causes more aggressive melanoma devel-
opment in zebrafish. This work was the first to demon-
strate the feasibility of high-throughput screening of
candidate cancer genes in zebrafish and establishes a
basis for guiding future approaches aiming to filter down
large cancer datasets.
In another application of this line, BRAF expression was
associated with a distinct gene signature that resembled
expression profiles of embryonic neural crest stem/pro-
genitor cells, thereby motivating White et al. [30] to
screen for suppressors of this embryonic phenotype. A
class of compounds, called inhibitors of dihydroorotate
dehydrogenase (DHODH), was found to selectively abro-
gate neural crest development in zebrafish as well as
melanoma growth in mouse xenografts and human cell
lines. Currently being followed in Phase I/II clinical trials,
the DHODH inhibitor leflunomide is a pivotal demon-
stration of how an embryonic phenotype can be translated
to findings about the human disease and lead molecules
from zebrafish research into clinical investigation.
Detailed live imaging of melanocytes in a temperature
sensitive mitfa (mitfavc7) mutant has provided novel
insights into the direct consequences of mitfa activityCurrent Opinion in Genetics & Development 2014, 24:38–45
40 Cancer genomicson tumorigenesis. Reduced mitfa activity caused a
dramatic increase in melanocyte cell division [31] and
was found to directly affect tumor morphology and for-
mation in the BRAF model [32]. As these findings could
be reversed with the restoration of mitfa’s activity, this
work substantiates the notion that mitfa is a modifier of
BRAF-driven melanoma and provides a functional link
between low MITF expression in patients with their poor
melanoma prognosis.
Embryonal rhabdomyosarcoma
Recent studies using a KRASG12D-driven model of embry-
onal rhabdomyosarcoma (ERMS) [11] have highlighted
the importance of the cell of origin as a determinant of
ERMS. For example, Ignatius et al. [33] used dynamic
cellular imaging of a mosaic transgenic rag2-KRASG12D
model to track the movement and evolution of ERMS cell
subpopulations in embryonic and adult zebrafish. Their
findings revealed new roles for differentiated ERMS cells
in tumor growth and suggest that mechanisms governing
their homeostatic maintenance in regulating growth could
be relevant considerations in developing potential thera-
peutic treatment.
In a similar approach, using promoters representing various
stages of muscle development (cdh15, rag2, mylz2), Storer
et al. [34] drove expression of KRASG12D and observed that
tumors that originated from the more progenitor like cells
were more invasive and undifferentiated. These tumors
were found to closely recapitulate subgroups of human
ERMS based on differentiation status and harbor unique
signaling pathways in each subgroup. Confirmation of
these pathways as therapeutic targets awaits further study
but demonstrates how cross-species oncogenomics can be
used to guide therapeutic targeting strategies.
Important insights have also been described in other
zebrafish models that cannot be described here [35–39]
(reviewed in [40,41,42,43]). It is apparent though that
some tumor types are better modeled in zebrafish than
others. Major areas that have not been as well developed
include reliable, penetrant models of pancreatic adeno-
carcinoma and intestinal carcinoma. While some attempts
in this direction have been made [44], these and other
diverse solid tumors will require further development.
Comparative oncogenomic approaches
One of the biggest challenges in experimental cancer
research is to demonstrate that the model in question
recapitulates the human disease. While zebrafish tumors
generally resemble their intended human cancers on a
histological level [1,7,8,24], there remain differences in
tumor spectrum, incidence and onset [3,5,24] that are
still not well understood. An emerging mode of compari-
son is through new genomic technologies, which, with
careful exploitation, may also point to genetic events that
are important for malignant human tumor evolution.Current Opinion in Genetics & Development 2014, 24:38–45 Several studies have begun to compare genomic
aberrations in zebrafish cancer to those in human.
Rudner et al. [45] employed high-density array compara-
tive genomic hybridization (aCGH) to zebrafish and
human T-ALL and found a small number of repeatedly
altered genes in zebrafish that also recur in human.
Greater overlap was shown in samples from advanced
stages of the disease, indicating a heightened conserva-
tion for genes under selective pressure. In another
study, Zhang et al. [46] sequenced a large cohort of
zebrafish malignant peripheral nerve sheath tumors
(MPNSTs) and distinguished amplified genes that
were shared with the human disease. While the
identification of these commonly mutated genes is a
promising first step, their experimental validation will
be critical toward demonstrating their biological signifi-
cance.
Our group recently investigated the full spectrum of
coding mutations in a zebrafish cancer through exome
sequencing of melanomas derived from BRAF and
NRAS-driven transgenic lines [76]. In probing for second-
ary genetic events important for melanoma development,
we found that the mutation burden in zebrafish melano-
mas was sparse compared to human cancer, and equally
heterogeneous to the point that cross-species comparisons
were difficult. Despite the mutation load, we were able to
quantify the multi-hit model of these engineered cancers
and highlight a potential new cooperating event with
BRAF and p53 mutation through the protein kinase A-
cyclic AMP pathway. The work provides the first insights
into the mutagenic processes of an engineered zebrafish
cancer and will be instructive in guiding future studies of
this type in zebrafish.
In particular, it is clear from our experience that there are
technical challenges in adapting sequencing tools to
zebrafish that require substantial optimization and de-
velopment. The tremendous diversity both within and
between zebrafish strains [47,48], nearly a magnitude
greater than that of human, combined with the duplicated
genome and other species-specific differences can com-
plicate alignment and overwhelm somatic mutation algor-
ithms with false calls. For this reason, extensive
confirmation of these mutations is paramount to avoid
errors and to ensure that the data are suitable for mean-
ingful analyses.
While these issues are being addressed, genomic pursuits
in zebrafish can focus on modalities that are more robust
to nuances in alignment, such as genomic copy number
changes and transcriptome profiles based on RNA-seq.
The latter strategy provides the additional advantage of
capturing a wider range of aberrations — important given
the heterogeneity — that together converge on a single
expression phenotype. This and optimization of available
tools will provide researchers far greater scope forwww.sciencedirect.com
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Important areas of zebrafish application in cancer research. (a) Multigenic screening involves the parallel testing of the oncogenic potential of
candidate cancer genes by injecting plasmids harboring gene of interests into embryos and monitoring for accelerated tumor onset in adult fish [28].
(b) Chemical libraries can be screened for activity in live zebrafish embryos using early embryonic phenotypic markers in 96 well plates. (c) Tumor
metastasis can be followed through the injection of GFP-labelled cell cultures in transparent zebrafish, called casper [17]. (d) One method of studying
cancer epigenetics in fish is to perform chromatin immunoprecipitation (ChIP) upon FACs sorted embryos followed by sequencing or expression
profiling. Embryos can be rapidly collected in tens of thousands of batches using the i-spawn [55].evaluating the relevance of zebrafish cancer and in pre-
scribing new targets and strategies for investigating the
human disease.
Future prospects and challenges
The zebrafish field has seen major growth over the past
10 years, as rapid application of transgenic and chemical
screening techniques have placed the fish in a unique
category of cancer models. But while creating and ana-
lyzing models of human cancer is useful, it ultimately is
not significantly advantageous to that done in mouse
models. For the fish to offer truly novel and important
insights into human cancer will require major inno-www.sciencedirect.com vations in technology and scale. Several areas are
particularly amenable to study in the zebrafish, as out-
lined below (Figure 1).
Multigenic changes in cancer
It is increasingly recognized that most human cancers are
wildly heterogeneous at genetic, and likely, epigenetic,
levels. To fully capture this complexity will require in
vivo models that can express not just one to four altered
genes, but potentially dozens. The increasing sophisti-
cation in making knockouts using TALENS [49,49] and
the Cas9/CRISPr [50] genome editing system has made it
possible to target nearly any candidate cancer gene in theCurrent Opinion in Genetics & Development 2014, 24:38–45
42 Cancer genomicsin vivo setting. Although CRISPr was initially thought to
be primarily useful for generating germline mutations
[50,51], more recent work has highlighted its capacity
for inducing somatic, biallelic disruptions in the F0
injected fish [52]. This is a tremendous advantage in
zebrafish, since thousands of embryos per day can be
generated, each of which can conceptually be injected
with a CRISPr and phenotypes directly assessed without
going to the next generation. In a typical fish facility
containing 2000–10 000 adult pairs of fish, the capacity to
test hundreds of candidate genes serially or in parallel
dwarfs what can be achieved in mouse models. It seems
likely that large-scale genetic screens using this method-
ology in zebrafish will be forthcoming in the near future,
complementing what has been done using ENU screens.
Chemical screening
Traditionally it has been difficult to perform large-
scale chemical screens in vivo. However, numerous
studies have now shown that the zebrafish is highly
amenable to large-scale screens, testing thousands
of compounds using detailed, in vivo phenotypic read-
outs. Although the majority of these screens have relied
upon ‘proxy’ embryonic phenotypes (i.e. an embryonic
gene program thought related to an adult cancer phe-
notype), better models of young fish with bona fide
cancer will make screening directly in young fish
possible.
Modeling metastasis
Responsible for nearly all deaths from solid tumors, the
capacity to accurately model metastasis in vivo is essential
to improving cancer survival. Our group (RW) has devel-
oped a transparent adult zebrafish, casper, that offers very
high sensitivity for imaging each of the steps of metastasis
[53]. Combining the optical superiority of this model with
all of the other key technologies (transgenesis, transplan-
tation, chemical screens, CRISPr’s), and with the pool of
available mutants generated from the Zebrafish Mutation
Project [54], the zebrafish offers a completely unique
model in which to deeply probe the biology of metastasis.
Epigenetics changes in cancer
A few studies (e.g. the discovery of SETDB1 in mela-
noma [28] as mentioned above) have just begun to
explore how the zebrafish can be used to understand
epigenetic contributions to cancer. This clearly emerging
field will greatly benefit from the genetic and chemical
screening tools available in the fish. Improvements in
performing core biochemical techniques (i.e. ChIP-seq,
methyl-seq, RNA-seq) along with zebrafish cell lines and
antibodies will potentially allow for probing of how epi-
genetic changes contribute to cancer phenotypes. Rapid
and large-scale transgenesis, particularly with inducible
systems, will be a key method to determine the temporal
dynamics of such changes, which will differ from purely
genetic changes seen in many tumor types.Current Opinion in Genetics & Development 2014, 24:38–45 Conclusion
As we enter the post-genomics era, the stage is set for
zebrafish researchers to capitalize on the strengths of this
model system and make significant contributions to cancer
research. Already, zebrafish have shown great potential
through proof-of-principle experiments involving high-
throughput screening [18,23,28,30] and detailed live
imaging [17,31,33,34] of embryonic and adult phenotypes.
New genomic technologies have provided greater resol-
ution for performing analyses of zebrafish cancer but
require careful application and interpretation. In order to
fully maximize the potential of zebrafish in cancer research,
strategic areas, such as systematic and scalable methods of
functional gene interrogation, using the multitude of exist-
ing models, should become a priority. Such focused efforts
will inevitably lead zebrafish toward an impact on cancer
research that is far more vital and productive.
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